Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that Takelda, a fixed-dose combination (FDC) of low-dose aspirin and Takepron (lansoprazole) for peptic ulcers, is now available in Japan.
Takelda combination tablets combine 100mg aspirin with 15mg lansoprazole and are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor.
The number of patients taking low-dose aspirin for prevention of the recurrence of cerebral infarction or myocardial infarction is increasing along with the rapidly aging population in Japan. As administration of low-dose aspirin may cause gastric or duodenal ulcers, preventing the onset of ulcers in that patient population is important. Domestic and international guidelines recommend combined administration with a proton pump inhibitor, especially for patients with a history of gastric or duodenal ulcers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze